Wordt geladen...
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
Nimotuzumab is a humanized anti-EGFR IgG1 monoclonal antibody and demonstrates a better safety profile than other anti-EGFR antibodies due to its intermediate affinity. Since it was approved in China for the treatment of nasopharyngeal cancer (NPC), it has been widely used in NPC and in many clinica...
Bewaard in:
| Gepubliceerd in: | Oncotarget |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078104/ https://ncbi.nlm.nih.gov/pubmed/27050148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8516 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|